China Baicaotang Ltd (CNBI) rated Buy with price target $6 by Ladenburg Thalmann
China Baicaotang Ltd (CNBI)
rated Buy with price target $6 by Ladenburg Thalmann.
China Baicaotang Medicine Limited, formerly Purden Lake Resource Corp., is engaged in pharmaceutical distribution, retail pharmacy and manufacture of pharmaceuticals and medical-related products through its three subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited (Liuzhou BCT), Hefeng Pharmaceutical Co. Limited (Hefeng Pharmaceutical) and Guangxi Liuzhou Baicaotang Medicine Retail Limited (BCT Retail), each of which is located in Guangxi Province, China. The Company operates in three segments: Pharmaceutical distribution, Retail pharmacy and Hefeng Pharmaceutical.
Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann
provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann
’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.